Jupiter Neurosciences Changes Auditors

Ticker: JUNS · Form: 8-K · Filed: 2025-04-21T00:00:00.000Z

Sentiment: neutral

Topics: auditor-change, accounting

TL;DR

Jupiter Neurosciences swapped auditors from WithumSmith+Brown to BDO USA, effective April 16, 2025.

AI Summary

Jupiter Neurosciences, Inc. announced on April 16, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, WithumSmith+Brown, PC, and has engaged BDO USA, LLP as its new principal accountant. This change was approved by the Audit Committee of the Board of Directors.

Why It Matters

A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors should monitor.

Risk Assessment

Risk Level: low — This filing reports a routine change of independent auditors, which is common for public companies and does not inherently indicate financial distress or significant operational changes.

Key Numbers

Key Players & Entities

FAQ

When was the change in certifying accountant effective?

The change in certifying accountant was effective as of April 16, 2025.

Who was Jupiter Neurosciences' previous certifying accountant?

Jupiter Neurosciences' previous certifying accountant was WithumSmith+Brown, PC.

Who is Jupiter Neurosciences' new certifying accountant?

Jupiter Neurosciences' new certifying accountant is BDO USA, LLP.

Who approved the change in certifying accountant?

The change in certifying accountant was approved by the Audit Committee of the Board of Directors.

What is the principal business of Jupiter Neurosciences, Inc.?

Jupiter Neurosciences, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).

From the Filing

0001641172-25-005506.txt : 20250421 0001641172-25-005506.hdr.sgml : 20250421 20250421123815 ACCESSION NUMBER: 0001641172-25-005506 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250416 ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250421 DATE AS OF CHANGE: 20250421 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 25851827 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 8-K 1 form8-k.htm false 0001679628 0001679628 2025-04-16 2025-04-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   April 16, 2025 Date of Report (Date of earliest event reported)   JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware   001-41265   47-4828381 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   1001 North US HWY 1 , Suite 504 , Jupiter , FL   33477 (Address of principal executive offices)   (Zip Code)   (561) 406-6154 Registrant’s telephone number, including area code   Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   JUNS   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging Growth Company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 4.01. Changes in Registrant’s Certifying Accountant.   Assurance Dimensions, LLC (“AD”), the independent registered public accounting firm for Jupiter Neurosciences, Inc. advised the Company that it was resigning as the independent registered accounting for the Company, effective as of April 16, 2025, as a result of its decision to discontinue its PCAOB registrants practice. Concurrent with such resignation, the Audit Committee of the Board of Directors of the Company approved the engagement of Cherry Bekaert LLP (“CB”) as

View on Read The Filing